| Males | Females | Total | p-value |
---|---|---|---|---|
At transplant (ml/min/1.73m2) | ||||
 Level 1: eGFR ≥90 | 288 (57.3%) | 65 (41.4%) | 353 (53.5%) | 0.0005a |
 Level 2: eGFR 60–89 | 141 (28.0%) | 56 (35.7%) | 197 (29.8%) |  |
 Level 3: eGFR 30–59 | 67 (13.3%) | 29 (18.5%) | 96 (14.5%) |  |
 Level 4: eGFR 15–29 | 7 (1.4%) | 4 (2.5%) | 11 (1.7%) |  |
 Level 5: eGFR < 15 | 0 (0.0%) | 3 (1.9%) | 3 (0.5%) |  |
 Not Recorded | 58 | 20 | 78 |  |
At inclusion visit (ml/min/1.73m2) | ||||
 Level 1: eGFR ≥90 | 156 (27.8%) | 48 (27.1%) | 204 (27.6%) | 0.0299a |
 Level 2: eGFR 60–89 | 277 (49.4%) | 70 (39.6%) | 347 (47.0%) |  |
 Level 3: eGFR 30–59 | 117 (20.9%) | 57 (32.2%) | 174 (23.6%) |  |
 Level 4: eGFR 15–29 | 5 (0.9%) | 1 (0.6%) | 6 (0.8%) |  |
 Level 5: eGFR < 15 | 6 (1.1%) | 1 (0.6%) | 7 (1.0%) |  |
At follow-up visit (ml/min/1.73m2) | ||||
 Level 1: eGFR ≥90 | 137 (24.4%) | 39 (22.0%) | 176 (23.9%) | 0.25903b |
 Level 2: eGFR 60–89 | 278 (49.6%) | 78 (44.1%) | 356 (48.2%) |  |
 Level 3: eGFR 30–59 | 133 (23.7%) | 54 (30.5%) | 187 (25.3%) |  |
 Level 4: eGFR 15–29 | 8 (1.4%) | 5 (2.8%) | 13 (1.8%) |  |
 Level 5: eGFR < 15 | 5 (0.9%) | 1 (0.6%) | 6 (0.8%) |  |